DUBLIN – Virionhealth Ltd., a newly funded U.K. startup, raised up to £13 million (US$17 million) in series A funding to take forward a novel approach for preventing and treating respiratory viral infections, which relies on a long-recognized quirk of viral replication that has long been overlooked by the biotechnology industry.